Form 4 for BCRX BIOCRYST PHARMACEUTICALS INC
Accepted 2025-12-19 00:00:00 ET · period of report 2025-12-17 · accession 0000882796-25-000038 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-12-19 | 2025-12-17 | BCRX | Ghias Babar | CFO | A - Grant | $0.00 | +121.7K | 268.7K | +83% | $0 |
| D | 2025-12-19 | 2025-12-17 | BCRX | Ghias Babar | CFO | A - Grant | $0.00 | +355.1K | 355.1K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-17 | A | A | 121,700 | $0.00 | 268,700 | D | — | — | (F1) Annual award of restricted stock units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant. |
| 2 | Derivative | Emp. Stock Option (Right to Buy) | 2025-12-17 | A | A | 355,050 | $0.00 | 355,050 | D | $7.13 · 2026-12-17 to 2035-12-17 | 355,050 Common Stock | (F2) Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. |